GST Council permits pharma cos to claim ITC on free samples, goods destroyed upon expiry from FY'28

The GST Council has approved a significant change in tax rules that will benefit pharmaceutical companies. Starting from fiscal year 2028, firms will be allowed to claim Input Tax Credit (ITC) on free drug samples provided to doctors. Previously, this credit was not available. Additionally, companies can now claim ITC on medicines that are destroyed due to expiry, a process that previously required the goods to be physically destroyed before claiming the credit.
This move is positive for the pharma sector as it improves cash flow and reduces the overall tax burden. For ITC, which is a major FMCG player with a substantial pharmaceutical division, this change could lead to better profitability and operational efficiency. It effectively lowers the cost of doing business by allowing the company to recover more of the taxes paid on these items.
Investors should monitor the company's quarterly results to see if this regulatory change leads to improved margins. While the benefit is set to begin in 2028, the long-term impact on the company's financial health and competitive positioning in the market will be key factors to watch.
Excerpt from BusinessLine
Pharma companies will be able to avail GST input tax credit (ITC) on free samples and on goods destroyed or written off upon expiry of shelf life from the next fiscal year. The GST Council, chaired by Union Finance Minister Nirmala Sitharaman and her state counterparts, had on Thursday approved the proposal to…Read the original at BusinessLine
Affected stocks
Bullish1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns ITC (ITC).
- Category: Sector.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update for ITC worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.











